Letraz 2.5 mg FC tablet.
PDF Leaflet Revision Date: 06 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women.
Dosage (summary)
2.5 mg once daily; treatment duration is 5 years or until tumor relapse.
Special Populations
- Elderly patients
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP2A6 and CYP2C19 inhibitors
- Tamoxifen may reduce LETRAZ levels
Contraindications
- Hypersensitivity to letrozole
- Premenopausal women
- Severe hepatic impairment
- Severe renal impairment
Common side effects
- Hot flushes
- Nausea
- Fatigue
Counselling Points
- Monitor bone density
- Caution advised when driving or operating machinery
Serious warnings
- Risk of bone fractures
- Increased cardiovascular events in patients with ischaemic heart disease
Important Disclaimer
The Letraz 2.5 mg FC tablet. professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
